There’s no doubt the “pricing crisis,” has taken a heavy toll on the reputation of the biopharmaceutical industry. The very industry that strives to improve and save peoples’ lives is at the center of a maelstrom of complaints about affordability and access to medicines.
Pushback on Rare Drug Prices: Not So Rare After All
By rarescience|2017-03-01T19:24:17-08:00February 28th, 2017|Legislative Updates, News|Comments Off on Pushback on Rare Drug Prices: Not So Rare After All